Epoprostenol intravenous - Actelion

Drug Profile

Epoprostenol intravenous - Actelion

Alternative Names: ACT-385781A; Caripul; EPO-ES; Epoprostenol ACT; Epoprostenol sodium thermostable - Actelion; Valetri; Veletri

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GeneraMedix
  • Developer Actelion Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pulmonary arterial hypertension

Most Recent Events

  • 21 Jul 2016 Launched for Pulmonary arterial hypertension in Greece (IV) befroe July 2016
  • 01 Jun 2015 Launched for Pulmonary arterial hypertension in France (IV)
  • 31 Dec 2014 Launched for Pulmonary arterial hypertension in Spain, New Zealand, Portugal, Poland, Belgium, Italy and Czech Republic (IV) before December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top